Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma.
Saito Y, Li Z, Lustberg M, Grenade C, Wesolowski R. Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma. Cancer Treatment And Research Communications 2018, 16: 9-12. PMID: 31299005, DOI: 10.1016/j.ctarc.2018.04.001.Peer-Reviewed Original ResearchNeuroendocrine carcinomaExceptional responseLarge cell neuroendocrine carcinomaEarly phase clinical trialsProgression-free survivalMetastatic prostate cancerCell neuroendocrine carcinomaNumber of malignanciesPrimary human tumorsMechanism of actionCancer cell linesFree survivalCell cycle arrestClinical trialsProstate cancerDNA damaging drugsNovel ATR inhibitorPatientsHuman tumorsM6620Cytotoxic effectsCycle arrestRemarkable responseDamaging drugsClonal evolution